论文部分内容阅读
目的探讨双侧原发性乳腺癌癌基因Her-2、p53、nm23及其雌激素受体(ER)、孕激素受体(PR)的表达情况,了解双侧原发性乳腺癌的生物学行为。方法研究分析20例双侧原发性乳腺癌相关癌基因Her-2、p53、nm23及其ER、PR表达情况,并与同期单侧乳腺癌比较。结果在同期650例乳腺癌中,双侧原发性乳腺癌20例,占3.07%,第一癌的ER、PR阳性率分别为60%和50%,第二癌的ER、PR阳性率分别为50%和40%,分别与同期单侧乳腺癌比较差异无统计学意义(P>0.05),第一和第二癌Her-2阳性表达率分别为40%(8/20)和30%(6/20);p53的阳性表达率分别为40%(8/20)和40%(8/20);nm23的阳性表达率分别为60%(12/20)和60%(12/20),它们与同期单侧乳腺癌比较差异均无统计学意义(P>0.05)。结论双侧原发性乳腺癌的相关癌基因Her-2、p53、nm23及其ER、PR受体改变没有特异性,与单侧乳腺癌的生物学行为相仿,治疗上应采取积极治疗措施。
Objective To investigate the expression of oncogene Her-2, p53, nm23, estrogen receptor (ER) and progesterone receptor (PR) in bilateral primary breast cancer and to understand the biology of bilateral primary breast cancer behavior. Methods The expressions of Her-2, p53, nm23 and ER, PR in 20 cases of primary breast cancer were analyzed and compared with that of unilateral breast cancer in the same period. Results In the same period of 650 cases of breast cancer, bilateral primary breast cancer in 20 cases, accounting for 3.07%, the first cancer ER, PR positive rates were 60% and 50%, respectively, the second cancer ER, PR positive rates (P> 0.05). The positive rates of Her-2 in the first and second cancer were 40% (8/20) and 30% respectively (6/20). The positive rates of p53 were 40% (8/20) and 40% (8/20), respectively. The positive rates of nm23 were 60% (12/20) and 60% ), They have no significant difference with the same period of unilateral breast cancer (P> 0.05). Conclusion There are no specific changes of Her-2, p53, nm23 and their ER, PR receptors in bilateral primary breast cancer, which are similar to the biological behavior of unilateral breast cancer. Active treatment should be taken in the treatment.